Concepedia

Glen Laird

GL

Statistics

Publications

11

Citations

632

H-Index

10

Active since

2003

Affiliations

Novartis (United States)(Current)

The University of Texas MD Anderson Cancer Center

Peter MacCallum Cancer Centre

Johannes Gutenberg University Mainz

Tris Pharma (United States)

Glen Laird is an author at Novartis (United States) specializing in oncology, medicine, and hematologic oncology.

Publications per year

2003–2013

11

Publications

11

A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients with Refractory Hematologic Malignancies

Francis J. Giles, Thomas Fischer, Jörge E. Cortes et al. · Clinical Cancer Research · 2006 · 314 citations

Medicine, Hematology, Pharmacology +17

Goodness‐of‐fit test for proportional subdistribution hazards model

Bingqing Zhou, Jason P. Fine, Glen Laird · Statistics in Medicine · 2013 · 61 citations

Public Health, Biostatistics, Oncology +15

Phase IA/II Study of Oral Panobinostat (LBH589), a Novel Pan- Deacetylase Inhibitor (DACi) Demonstrating Efficacy in Patients with Advanced Hematologic Malignancies.

Oliver G. Ottmann, Andrew Spencer, H. Miles Prince et al. · Blood · 2008 · 50 citations

Medicine, Oncology, Pharmacology +13

A Bayesian Case Study in Oncology Phase I Combination Dose-Finding Using Logistic Regression with Covariates

Stuart Bailey, Beat Neuenschwander, Glen Laird et al. · Journal of Biopharmaceutical Statistics · 2009 · 45 citations

Public Health, Biostatistics, Oncology +17

Psychiatric Comorbidity and Not Completing Jail‐based Substance Abuse Treatment

Thomas M. Brady, Christopher Krebs, Glen Laird · American Journal on Addictions · 2004 · 42 citations

Social Sciences, Psychiatry, Psychology +17

1–5 of 11